Page last updated: 2024-12-06
versiconol acetate
Description
versiconol acetate: structure given in first source; RN given refers to (-)-isomer; RN for cpd without isomeric designation not avail 2/92 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
(3S)-versiconol acetate : An optically active form of versiconol acetate having 3S-configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
versiconol acetate : An acetate ester that is the O-acetyl derivative of versiconol. An intermediate in the biosynthesis of aflatoxin. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
Cross-References
Synonyms (13)
Synonym |
brn 2067482 |
(3s)-4-hydroxy-3-(1,3,6,8-tetrahydroxy-9,10-dioxo-9,10-dihydroanthracen-2-yl)butyl acetate |
CHEBI:72681 |
(3s)-versiconol acetate |
versiconol acetate |
70979-72-5 |
unii-k9tga2z1wa |
k9tga2z1wa , |
C20506 |
9,10-anthracenedione, 2-(3-(acetyloxy)-1-(hydroxymethyl)propyl)-1,3,6,8-tetrahydroxy-, (s)- |
9,10-anthracenedione, 2-((1s)-3-(acetyloxy)-1-(hydroxymethyl)propyl)-1,3,6,8-tetrahydroxy- |
versiconol acetate, (-)- |
Q27140074 |
Drug Classes (1)
Class | Description |
versiconol acetate | An acetate ester that is the O-acetyl derivative of versiconol. An intermediate in the biosynthesis of aflatoxin. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (5)
Timeframe | Studies, This Drug (%) | All Drugs % |
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (20.00) | 18.2507 |
2000's | 4 (80.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |